$882.96 Million in Sales Expected for Horizon Therapeutics Public Limited (NASDAQ:HZNP) This Quarter

Analysts expect Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) to report $882.96 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Horizon Therapeutics Public’s earnings, with the highest sales estimate coming in at $941.30 million and the lowest estimate coming in at $860.21 million. Horizon Therapeutics Public posted sales of $342.41 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 157.9%. The company is expected to report its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Horizon Therapeutics Public will report full year sales of $4.00 billion for the current year, with estimates ranging from $3.96 billion to $4.07 billion. For the next financial year, analysts anticipate that the company will report sales of $4.74 billion, with estimates ranging from $4.61 billion to $4.91 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Horizon Therapeutics Public.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.27 by $0.14. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $995.90 million. Horizon Therapeutics Public had a net margin of 16.57% and a return on equity of 26.66%. Horizon Therapeutics Public’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.28 earnings per share.

A number of research firms have issued reports on HZNP. Morgan Stanley boosted their price target on Horizon Therapeutics Public from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 2nd. StockNews.com initiated coverage on Horizon Therapeutics Public in a report on Thursday, March 31st. They set a “hold” rating for the company. Piper Sandler cut their price target on shares of Horizon Therapeutics Public from $143.00 to $133.00 in a report on Wednesday, January 26th. Zacks Investment Research upgraded shares of Horizon Therapeutics Public from a “strong sell” rating to a “hold” rating and set a $104.00 price objective for the company in a research note on Thursday, March 3rd. Finally, Oppenheimer began coverage on shares of Horizon Therapeutics Public in a research note on Monday, March 14th. They issued an “outperform” rating and a $140.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Horizon Therapeutics Public currently has an average rating of “Buy” and an average target price of $133.67.

In other Horizon Therapeutics Public news, CFO Paul W. Hoelscher sold 663 shares of Horizon Therapeutics Public stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $110.00, for a total transaction of $72,930.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Timothy P. Walbert sold 25,000 shares of the stock in a transaction that occurred on Friday, January 28th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. The disclosure for this sale can be found here. Insiders sold 580,624 shares of company stock valued at $60,865,020 over the last 90 days. Insiders own 2.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC increased its position in shares of Horizon Therapeutics Public by 2.0% in the 4th quarter. Nuveen Asset Management LLC now owns 7,045,423 shares of the biopharmaceutical company’s stock worth $759,215,000 after purchasing an additional 135,736 shares during the last quarter. Janus Henderson Group PLC grew its stake in Horizon Therapeutics Public by 3.9% in the third quarter. Janus Henderson Group PLC now owns 6,053,732 shares of the biopharmaceutical company’s stock worth $663,123,000 after purchasing an additional 229,538 shares in the last quarter. State Street Corp increased its holdings in Horizon Therapeutics Public by 0.6% in the fourth quarter. State Street Corp now owns 5,474,308 shares of the biopharmaceutical company’s stock valued at $589,911,000 after buying an additional 32,291 shares during the last quarter. Allianz Asset Management GmbH raised its stake in Horizon Therapeutics Public by 2.4% during the third quarter. Allianz Asset Management GmbH now owns 3,006,452 shares of the biopharmaceutical company’s stock valued at $329,327,000 after buying an additional 70,560 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Horizon Therapeutics Public by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 2,905,298 shares of the biopharmaceutical company’s stock worth $312,637,000 after buying an additional 90,703 shares during the last quarter. 88.11% of the stock is owned by institutional investors.

HZNP stock opened at $110.49 on Friday. The company has a quick ratio of 2.90, a current ratio of 3.16 and a debt-to-equity ratio of 0.55. The company has a market cap of $25.32 billion, a price-to-earnings ratio of 49.55, a PEG ratio of 1.57 and a beta of 1.12. The business has a fifty day simple moving average of $104.07 and a 200-day simple moving average of $104.13. Horizon Therapeutics Public has a 52 week low of $83.42 and a 52 week high of $120.54.

Horizon Therapeutics Public Company Profile (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Stories